Safety issues have felled another member of the phosphatidylinositol 3-kinase (PI3K) inhibitor class, TG Therapeutics, Inc.’s lymphoma drug Ukoniq (umbralisib), and with it combination use with a new anti-CD20 monoclonal antibody, ublituximab, in oncology indications.
On 15 April, TG Therapeutics announced it had withdrawn the pending US applications for the combination of ublituximab and umbralisib...





